P
Paul Workman
Researcher at Institute of Cancer Research
Publications - 563
Citations - 41681
Paul Workman is an academic researcher from Institute of Cancer Research. The author has contributed to research in topics: Cancer & Hsp90. The author has an hindex of 102, co-authored 547 publications receiving 38095 citations. Previous affiliations of Paul Workman include Institut Gustave Roussy & AstraZeneca.
Papers
More filters
Journal ArticleDOI
Guidelines for the welfare and use of animals in cancer research
Paul Workman,Eric O. Aboagye,Frances R. Balkwill,Allan Balmain,G Bruder,D.J. Chaplin,John A. Double,Jeffrey I. Everitt,D A H Farningham,D A H Farningham,Martin J. Glennie,Lloyd R. Kelland,V Robinson,Ian J. Stratford,Gillian M. Tozer,Susan A. Watson,Stephen R. Wedge,Suzanne A. Eccles,V Navaratnam,S Ryder +19 more
TL;DR: New guidelines on the welfare and use of animals in cancer research are provided, including recommendations on all aspects of cancer research, including: study design, statistics and pilot studies; choice of tumour models and humane endpoints.
Journal ArticleDOI
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Georgios Vlachogiannis,Somaieh Hedayat,Alexandra Vatsiou,Yann Jamin,Javier Fernández-Mateos,Khurum Khan,Khurum Khan,Andrea Lampis,Katherine Eason,Ian Said Huntingford,Rosemary Burke,Mihaela Rata,Dow-Mu Koh,Dow-Mu Koh,Nina Tunariu,Nina Tunariu,David J. Collins,Sanna Hulkki-Wilson,Chanthirika Ragulan,Inmaculada Spiteri,Sing Yu Moorcraft,Ian Chau,Sheela Rao,David Watkins,Nicos Fotiadis,Maria Antonietta Bali,Maria Antonietta Bali,Mahnaz Darvish-Damavandi,Hazel Lote,Hazel Lote,Zakaria Eltahir,Elizabeth C Smyth,Ruwaida Begum,Paul A. Clarke,Jens C. Hahne,Mitchell Dowsett,Johann S. de Bono,Paul Workman,Anguraj Sadanandam,Matteo Fassan,Owen J. Sansom,Suzanne A. Eccles,Naureen Starling,Chiara Braconi,Chiara Braconi,Andrea Sottoriva,Simon P. Robinson,David Cunningham,Nicola Valeri,Nicola Valeri +49 more
TL;DR: Responses to anticancer agents ex vivo in organoids and PDO-based orthotopic mouse tumor xenograft models with the responses of the patients in clinical trials are compared to suggest that PDOs can recapitulate patient responses in the clinic and could be implemented in personalized medicine programs.
Journal ArticleDOI
Combinatorial drug therapy for cancer in the post-genomic era
TL;DR: The extraordinary intratumor genetic heterogeneity in cancers revealed by deep sequencing explains why de novo and acquired resistance arise with molecularly targeted drugs and cytotoxic chemotherapy, limiting their utility.
Journal ArticleDOI
Hsp90 molecular chaperone inhibitors: are we there yet?
Len Neckers,Paul Workman +1 more
TL;DR: Success will likely lie in treating cancers that are addicted to particular driver oncogene products that are sensitive Hsp90 clients, as well as malignancies in which buffering of proteotoxic stress is critical for survival.
Journal ArticleDOI
Imaging biomarker roadmap for cancer studies.
James P B O'Connor,Eric O. Aboagye,Judith E. Adams,Hugo J.W.L. Aerts,Hugo J.W.L. Aerts,Sally F. Barrington,Ambros J. Beer,Ronald Boellaard,Sarah E. Bohndiek,J. Michael Brady,Gina Brown,David L. Buckley,Thomas L. Chenevert,Laurence P. Clarke,Sandra Collette,Gary Cook,Nandita M. deSouza,John Dickson,Caroline Dive,Jeffrey L. Evelhoch,Corinne Faivre-Finn,Ferdia A. Gallagher,Fiona J. Gilbert,Robert J. Gillies,Vicky Goh,John R. Griffiths,Ashley M. Groves,Steve Halligan,Adrian L. Harris,David J. Hawkes,Otto S. Hoekstra,Erich P. Huang,Brian Hutton,Edward F. Jackson,Gordon C Jayson,Andrew J. I. Jones,Dow-Mu Koh,Denis Lacombe,Philippe Lambin,Nathalie Lassau,Martin O. Leach,Ting-Yim Lee,Edward Leen,Jason S. Lewis,Yan Liu,Mark F. Lythgoe,Prakash Manoharan,Ross J. Maxwell,Kenneth A. Miles,Bruno Morgan,Steve Morris,Tony Ng,Anwar R. Padhani,Geoff J M Parker,Mike Partridge,Arvind P. Pathak,Arvind P. Pathak,Andrew C. Peet,Shonit Punwani,Andrew R. Reynolds,Simon P. Robinson,Lalitha K. Shankar,Ricky A. Sharma,Dmitry Soloviev,Sigrid Stroobants,Daniel C. Sullivan,Stuart A. Taylor,Paul S. Tofts,Gillian M. Tozer,Marcel van Herk,Simon Walker-Samuel,James Wason,Kaye J. Williams,Paul Workman,Thomas E. Yankeelov,Kevin M. Brindle,Lisa M. McShane,Alan Jackson,John C. Waterton +78 more
TL;DR: Experts assembled to review, debate and summarize the challenges of IB validation and qualification produced 14 key recommendations for accelerating the clinical translation of IBs, which highlight the role of parallel (rather than sequential) tracks of technical validation, biological/clinical validation and assessment of cost-effectiveness.